Book Review: ‘No More Tears’ scrutinizes the legacy of health giant Johnson & Johnson
The Dark Secrets of Johnson & Johnson,” veteran reporter Gardiner Harris scrutinizes the legacy of health care giant Johnson ...
Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study
Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients ...
J&J highlights Tremfya’s efficacy against psoriatic arthritis in Phase 3 trial win
Johnson & Johnson (JNJ) reports a Phase 3 success for its anti-inflammatory drug Tremfya in treating psoriatic arthritis.
J&J’s experimental antiviral drug shows promise against COVID-19 and emerging coronaviruses
This development comes at a time when pharmaceutical firms are discontinuing discovery efforts in next-generation COVID-19 treatments.
Guggenheim Reiterates Neutral Rating for Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson (NYSE:JNJ – Get Free Report)‘s stock had its “neutral” rating reaffirmed by analysts at Guggenheim in a ...
Johnson & Johnson’s (JNJ) “Outperform” Rating Reiterated at Royal Bank of Canada
Johnson & Johnson (NYSE:JNJ – Get Free Report)‘s stock had its “outperform” rating reaffirmed by Royal Bank of Canada in a research note issued on Wednesday,Benzinga reports. They currently have a ...
JNJ vs. PFE: Which Drug Giant is a Better Buy Now?
Johnson & Johnson JNJ and Pfizer PFE are two of the world’s largest pharmaceutical companies with diversified healthcare ...
Medical Dialogues4d
JnJ closes Intra-Cellular Therapies acquisition
Johnson & Johnson has announced it has completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies is now part of Johnson & Johnson and will operate as ...
Worried About the Economy? 2 No-Brainer Buys to Shield Your Portfolio.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
MassDevice5d
Johnson & Johnson has positive dual-energy ablation data
Johnson & Johnson MedTech (NYSE: JNJ) announced 12-month data from its SmartfIRE clinical trial of the ThermoCool SmartTouch ...
What’s next for Johnson and Johnson after third failed attempt to settle talc laws
In his decision, Lopez pointed to issues with the voting process and called a third-party release for Kenvue (NYSE: KVUE) ...
Marketplace5d
Johnson & Johnson tried 3 times to resolve talc suits in bankruptcy court. It didn’t work.
A federal bankruptcy judge has rejected Johnson & Johnson’s latest attempt to settle lawsuits that allege its talc baby ...